Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is becoming harder and harder to avoid the subversive thought that this was a scam right from the start. The principles have made their fortunes, all believers have lost although some clever people have made money predicting the movement and trading.
Is there anyone reading this that can drop by the offices in Texas to see if there are actually people there?
why are there only 2 post in the last month..are you all losing interest in bpth
As an old investor (both by age and by length of time in this mess) I seldom bother to check to see what is going on; when you've been 200:1 buggered what is the point? (yes, that is a whine, live with it). However I took a look today to see if the world is any closer to a cancer cure and was disappointed that the BPTH web site is three years or more out of date; it refers to:
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.
and:
- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.
and:
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
I took a quick look at the 2020 slide show :
http://www.biopathholdings.com/wp-content/uploads/2020/01/BPTH_Corp_Presentation_Jan_2020.pdf
and the results on slide 8 9 10 are what I remember (no I didn't verify) from 2017
I remember the halcion days of 2016 and 2017, it seems the company hasn't moved on since then!!! Does anyone know if they are even still working on this or are they just sitting with their thumbs up their bums enjoying a free ride until the money runs out?
Just asking.
don'tyou find it interesting that BOD has lost most of the original directors.it's now a stacked BOD that will rubber stamp anything PN wants to do.
My hope is PN realizing he is not getting any younger!
My hope is PN realizing he is not getting any younger!
Folks we are still years away from FDA approval.
Until PN gets the lion share of the 660k shares approved as compensation do you really expect a drive for FDA approval?
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
GlobeNewswire GlobeNewswire•January 8, 2020
HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update from several clinical development programs and a 2020 business overview.
“We enter 2020 with robust development plans to commence several key clinical trials that are expected to advance our DNAbilize antisense RNAi nanoparticle technology in a number of important oncology indications for which there are limited treatment options,” said Peter H. Nielsen, President and Chief Executive Officer of Bio-Path. “We are excited to initiate a number of important studies across our development pipeline and anticipate reporting key clinical datapoints from those studies later in the year.”
Phase 2 Study of Prexigebersen in Untreated and Refractory/Resistant Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Patients
In March 2019, Bio-Path announced a revised strategy for the Stage 2 portion of its Phase 2 clinical trial of prexigebersen in combination with frontline chemotherapy. Bio-Path’s amended Stage 2 of the Phase 2 clinical trial will treat two cohorts of patients. The first cohort is to include untreated AML patients as existed in the pre-amended trial but with the addition of untreated, high-risk MDS patients. The second cohort is to include refractory/relapsed AML patients and high-risk MDS patients. Both cohorts of patients are planned to be treated with the combination of prexigebersen, decitabine and venetoclax. The Company is finalizing amendments to add this combination treatment to Stage 2 of the Phase 2 clinical trial.
The first step in the revised strategy involved testing the safety of the combination of prexigebersen and decitabine. In November 2019, the Company announced successful completion of this safety testing in AML and MDS patients in Stage 2 of the Phase 2 clinical study. The safety segment of Stage 2 of the Phase 2 clinical trial comprised six evaluable patients who were treated with the combination of prexigebersen and decitabine. Although the combination of prexigebersen and decitabine is not the treatment currently planned for the efficacy evaluation of Stage 2 of the Phase 2 clinical trial, the efficacy profile in this safety segment of the study was very encouraging, with 50% of patients having a response, including two patients (33%) showing complete responses with incomplete hematologic recovery and one patient (17%) showing partial response. For reference, in this class of AML and MDS patients, the complete response rate to treatment with decitabine alone is approximately 20%. Some patients are continuing to receive treatment.
The next step in this Stage 2 of the Phase 2 program will be the safety testing of prexigebersen in combination with decitabine and venetoclax in six evaluable patients drawn from either of the two cohorts of untreated AML and high-risk MDS patients or relapsed/refractory AML and high-risk MDS patients. The Company currently expects to initiate this safety testing in the second quarter of 2020. Assuming successful completion of this safety testing, the Company plans that it would then initiate the efficacy testing of this triple combination in the two cohorts of patients. In 2020, Bio-Path intends to continue its efforts to expand the number of sites, including European-based sites, to enhance patient enrollment.
The clinical design of the Stage 2 portion of the Phase 2 clinical trial calls for an interim analysis of each cohort’s results after each cohort has treated 19 evaluable patients. If the results from either or both patient cohorts exceed expectations for current standard-of-care therapy, the Company expects that plans for a pivotal trial would be discussed with the FDA.
Phase 2a Study of Prexigebersen to treat Chronic Myeloid Leukemia (CML) in Tyrosine Kinase Inhibitor Failures and Accelerated and Blast Phase CML Patients
Bio-Path plans to enroll patients in a Phase 2a clinical study of prexigebersen in combination with the frontline therapy, dasatinib, for the treatment of CML in tyrosine kinase inhibitor failures and accelerated and blast phase patients in 2020. The trial is expected to be conducted at The University of Texas MD Anderson Cancer Center as a potential salvage therapy for accelerated and blast phase CML patients and will expand to other sites if feasible. Recent advances in the treatment of chronic phase CML patients with tyrosine inhibitors has limited the availability of these patients for the Bio-Path Phase 2a. As a result, the continuation of this study is being evaluated based on the potential for patient availability and clinical trial site expansion. If this Phase 2a study is advanced, it will evaluate two cohorts of three evaluable patients at two doses (60 mg/m2 and 90 mg/m2) of prexigebersen in combination with dasatinib.
Phase 1 Study of Prexigebersen in Patients with Advanced Solid Tumors
In late 2019, Bio-Path filed an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of prexigebersen in patients with advanced solid tumors, including ovarian and uterine, pancreatic and breast cancer. This trial is expected to commence after the IND has been cleared by the FDA, which we currently anticipate being in 2020, at several leading cancer centers and will evaluate the safety of prexigebersen in these patients. Assuming positive Phase 1 results, the Company expects it would advance to a Phase 1b clinical trial of prexigebersen in combination with frontline therapy in these same advanced solid tumor patients.
Phase 1 Study of BP1002 in Refractory or Relapsed Lymphoma Patients and Chronic Lymphocytic Leukemia Patients
In November 2019 the FDA cleared the IND for BP1002 (liposomal Bcl-2), the Company’s second drug candidate, to begin a Phase 1 clinical trial to evaluate BP1002 as a treatment for refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. This study is expected to commence in the first half of 2020 and is expected to be conducted at several premier oncology centers, including the University of Texas MD Anderson Cancer Center, and is planned to evaluate the safety of BP1002 in several dose escalating cohorts to determine a maximum tolerated dose.
Preclinical Development of BP1003
The Company continues to advance its third investigational drug candidate, BP1003, for the treatment of advanced solid tumors, including pancreatic cancer. BP1003 is an antisense RNAi nanoparticle targeting the Stat3 protein.
In 2020 Bio-Path expects to complete several IND-enabling studies for BP1003. If those studies are successful, Bio-Path expects that it would file an IND in late 2020 for the first-in-humans Phase 1 study of BP1003 in patients with refractory/metastatic solid tumors including pancreatic, non-small cell lung cancer, and colorectal cancers.
BP1003 has demonstrated efficacy in combination with frontline therapies in animals against pancreatic tumors.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.For more information, please visit the Company's website at http://www.biopathholdings.com.
The FDA approves a new drug for pancreatic cancer. Where is BPTH's drug?
https://www.ibtimes.com/fda-approves-one-kind-drug-treating-advanced-pancreatic-cancer-2894114
One thing is certain. PN certainly makes sure he is paid.
Increase shareholder dilution by 23% to get paid.
The fox is in the hen house again.
The BOD diluting the float for their own gain.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Bio-Path Holdings, Inc. (the “Company”) held its 2019 annual meeting (the “2019 Annual Meeting”) of stockholders of the Company on December 19, 2019 in The Woodlands, Texas. At the 2019 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (the “2017 Plan”) to increase the number of shares of the Company’s common stock that may be issued under the 2017 Plan by 600,000 shares for a total of 660,000 shares. A description of the 2017 Plan is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 1, 2019 under the heading “Proposal Two: Approval Of An Amendment To The Company’s 2017 Stock Incentive Plan To Increase The Number Of Shares Of Common Stock That May Be Issued Under The Plan By 600,000 Shares For A Total Of 660,000 Shares,” which description is incorporated herein by reference. This summary is qualified in its entirety by the full text of the Amendment, which is filed as Exhibit 10.1 hereto, and the 2017 Plan, which is filed as Exhibit 10.2 hereto.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2019 Annual Meeting, the Company’s stockholders: (i) elected the five persons listed below under Proposal 1 to serve as directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified; (ii) approved the Amendment to the 2017 Plan; (iii) approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers; (iv) approved, on a non-binding advisory basis, the frequency of “every three years” for the stockholders’ non-binding advisory vote on the compensation of the Company’s named executive officers; and (v) ratified and approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2019. The following describes the results of the voting at the 2019 Annual Meeting:
Proposal 1: For the election of directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified:
Peter H. Nielsen 326,250 -- 30,833 -- 1,790,089
Heath W. Cleaver 321,104 -- 35,979 -- 1,790,089
Paul D. Aubert 321,532 -- 35,551 -- 1,790,089
Martina Molsbergen 331,191 -- 25,892 -- 1,790,089
Douglas P. Morris 331,836 -- 25,247 -- 1,790,089
Proposal 2: For the approval of the Amendment to the 2017 Plan:
214,416 139,538 -- 3,129 1,790,089
Proposal 3: For the non-binding advisory approval of the compensation of the Company’s named executive officers:
304,230 46,537 -- 6,316 1,790,089
Proposal 4: For the non-binding advisory approval of the frequency of stockholders’ non-binding advisory vote on the compensation of the Company’s named executive officers:
101,550 85,884 160,402 9,247
Proposal 5: For the ratification and approval of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2019:
2,049,920 54,045 -- 43,207 --
Based on the stockholders’ advisory vote and other factors, the board of directors of the Company resolved that future non-binding stockholder advisory votes on the compensation of the Company’s named executive officers will be conducted every three years until such time as the Company holds another stockholder advisory vote on the frequency of advisory votes by the stockholders on the compensation of the Company’s named executive officers.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-PATH HOLDINGS, Inc.
Dated: December 23, 2019 By: /s/ Peter H. Nielsen
Peter H. Nielsen
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Description
10.1 First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan
10.2 Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 27, 2017).
--------------------------------------------------------------------------------
Exhibit 10.1
FIRST AMENDMENT
TO
BIO-PATH HOLDINGS, INC.
2017 STOCK INCENTIVE PLAN
This First Amendment (the “First Amendment”) to that certain Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (the “Plan”) of Bio-Path Holdings, Inc., a Delaware corporation (the “Company”), is adopted as of October 28, 2019, subject to the approval of the stockholders of the Company. All capitalized and undefined terms used herein shall have the meanings ascribed to such terms in the Plan.
WHEREAS, pursuant to subsection 18.1 of the Plan, the Board of Directors of the Company (the “Board”) is authorized to amend the Plan, provided that any amendment that would increase the number of Shares reserved for issuance under the Plan (other than in accordance with an adjustment pursuant to subsection 17.1 of the Plan) must be approved by the stockholders of the Company within twelve (12) months before or after such amendment; and
WHEREAS, the Board unanimously approved this First Amendment to increase the number of Shares reserved for issuance under the Plan as set forth herein, subject to the approval of the stockholders of the Company, and has recommended that the stockholders of the Company approve this First Amendment.
NOW, THEREFORE, in connection with the foregoing, the Plan is hereby amended as follows, subject to approval by the stockholders of the Company:
Subsection 4.1 is hereby deleted in its entirety and replaced with the following:
1. “4.1 Share Reserve. Except as otherwise provided in this Section 4 and subsection 17.1, the maximum number of Shares that may be issued with respect to Awards granted pursuant to this Plan shall not exceed 660,000. All or any portion of the Share reserve may be issued in connection with the exercise of Incentive Stock Options. The Shares issued pursuant to this Plan may be authorized but unissued Shares or may be issued Shares that have been repurchased or acquired by the Company, including shares purchased by the Company on the open market for purposes of the Plan.”
Except as amended and modified by this First Amendment, the Plan shall continue in full force and effect, and the Plan and this First Amendment shall be construed as one and the same instrument.
The foregoing is hereby acknowledged as being the First Amendment to the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as adopted by the Board on October 28, 2019, subject to approval by the Company’s stockholders.
BIO-PATH HOLDINGS, INC.
By: /s/ Peter H. Nielsen
Name: Peter H. Nielsen
Title: President and Chief Executive Officer
HC Wainwright had it at 28.00, but then revised it to 25.00. BPTH having a good move today, but I see no news that is boosting price. Volume heavy.
who has the 28 target ?
With all these analyst's upgrades, why is this stock not moving?? Price targets of 25 and 28 should have given the stock a nice "sustaining" bump.
Trial listed
https://clinicaltrials.gov/ct2/show/NCT04196257
BPTH volume in trading and stocktwits posts both declining by day.
Paullee - thanks for the info.
First time I have seen these details from this co.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc.
http://stonegateinc.com/reports/BPTH%20DEC%202019.pdf
Our market cap now equals cash on hand.
The market is not giving us any premium for the value of our technology.
If this valuation continues in 6 months our PPS will equal $6.50 and $5.00 in a year as our cash decreases.
I suspect no real valuation based on our technology until a partnership or drug approval.
Stocktwits shows this stock now has a large public following which it never had in the past.
If PN gets a partner or FDA approval of any drug the PPS like Alice is "going the Moon."
From Fidelity, yes thing are looking up for them. About time.
On December 4, 2019 Zacks Investment Research, Inc. upgraded BIO PATH HOLDINGS INC (BPTH) from HOLD to BUY.
Don’t know... I just buy the breakout
Why the big move? No news that I see.
Thanks SJ, I think we were just way too early to the party. If I was younger I might pick up some, but at this stage what I have will have to do . Will sell some for tax loss , at least I will get some benefit . Sure would be nice if they could get some licenses done .
Too, I suspect the positive numbers of 50% were not enough.
It is way to small a sample to draw any conclusions except for safety. Remember what happened last time!
The real news is again....NO SIDE EFFECTS!
If BPTH drops below $5 I may begin to buy again.
SJ, any idea why the results are viewed as negative, or I was thinking that they look to me like they are shot gunning without being able to complete a trial anywhere close to prediction.
Raising money before the results were announced is beginning to look like a stroke of genius.
The safety results are disappointing to the market so far.
Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
GlobeNewswire GlobeNewswire•November 26, 2019
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the successful completion of the safety testing of prexigebersen in combination with decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients in Stage 2 of the Phase 2 clinical study. The safety segment of Stage 2 of the Phase 2 clinical trial comprised six evaluable patients who were treated with the combination of prexigebersen and decitabine.
“We are especially pleased to have successfully completed this key safety segment of our Phase 2 study as it allows us to move forward to the next segment of this important clinical study, which is the final, efficacy portion of Stage 2 of the Phase 2 study,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We are in the process of completing the documentation to submit for final approval of this last portion of Stage 2 of the Phase 2 study. These results are encouraging and give us greater confidence in the successful development of this very promising combination therapy for AML and MDS patients."
Although the treatment combination of prexigebersen and decitabine is not the treatment planned for the efficacy evaluation of Stage 2 of the Phase 2 clinical trial, the efficacy profile in this safety segment of the study was encouraging with 50% of patients having a response, including two patients (33%) showing complete responses with incomplete hematologic recovery and one patient (17%) showing partial response. For reference, in this class of AML and MDS patients, the complete response rate to treatment with decitabine alone is approximately 20%. Some patients are continuing to receive treatment.
As previously reported, Stage 1 of the Phase 2 clinical trial, which treated de novo AML patients with a combination of low dose cytarabine (LDAC) and prexigebersen, demonstrated similar safety results and efficacy compared favorably to treatment of this class of patients with LDAC alone. We believe that prexigebersen with its promising efficacy and safety profile, has the potential to be an ideal combination candidate with frontline therapy. The recent approval of the frontline therapy venetoclax provided an opportunity for adding prexigebersen to the combination of venetoclax and decitabine for the treatment of AML and MDS patients. The first step in this process was establishing the safety of combining prexigebersen and decitabine prior to proceeding to a combination treatment of prexigebersen, decitabine and venetoclax.
Bio-Path’s amended Stage 2 of the Phase 2 clinical trial will have two cohorts of patients. The first cohort will include untreated AML patients as existed in the pre-amended trial but with the addition of untreated high risk MDS patients, and a second cohort will include refractory/relapsed AML patients and high risk MDS patients. Both cohorts of patients will be treated with the combination of prexigebersen, decitabine and venetoclax. The Company is finalizing amendments to add this combination treatment to Stage 2 of the Phase 2 clinical trial.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and is in the process of filing an IND for a Phase 1 clinical trial for solid tumors. The Company’s second product BP1002, which targets the Bcl-2 protein, will be evaluated for the treatment of lymphoma and solid tumors. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2020.
"Item 1.01 Entry Into a Material Definitive Agreement.
On November 21, 2019, Bio-Path Holdings, Inc. (the “Company”) and several institutional investors entered into securities purchase agreements (the “Purchase Agreements”), pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 808,080 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), and warrants to purchase up to 606,060 shares of Common Stock (the “Investor Warrants”) for a purchase price of $9.90 per Share and accompanying Investor Warrant and gross proceeds of approximately $8.0 million. Subject to certain ownership limitations, the Investor Warrants will be exercisable immediately upon issuance, have a term of five years from issuance and have an exercise price of $9.90 per share. The number of shares issuable upon exercise of the Investor Warrants and the exercise price of the Investor Warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.
On November 20, 2019, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company, on a reasonable best efforts basis, in connection with the Registered Direct Offering. The Company has agreed to pay the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds received in the Registered Direct Offering. In addition, the Company has agreed to grant to the Placement Agent warrants to purchase up to 48,485 shares of Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants will be substantially on the same terms as the Investor Warrants, except that the Placement Agent Warrants will have an exercise price of $12.375 per share and will have a term of five years from the effective date of the Registered Direct Offering. The Company will also reimburse the Placement Agent $85,000 for non-accountable expenses and $10,000 for clearing expenses.
The Shares, Investor Warrants, Placement Agent Warrants and the shares issuable upon exercise of the Investor Warrants and Placement Agent Warrants will be issued pursuant to a prospectus supplement dated as of November 21, 2019, which was filed with the Securities and Exchange Commission in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-231537), which became effective on June 5, 2019, and the base prospectus dated as of June 5, 2019 contained in such registration statement.
The net proceeds to the Company from the Registered Direct Offering, after deducting the Placement Agent’s fees and expenses and the Company’s estimated offering expenses, and excluding the proceeds, if any, from the exercise of the Investor Warrants and the Placement Agent Warrants, are expected to be approximately $7.3 million. The Registered Direct Offering is expected to close on or about November 25, 2019, subject to the satisfaction of customary closing conditions. The Company currently intends to use these net proceeds for working capital and general corporate purposes.
The legal opinion of Winstead PC relating to the legality of the issuance and sale of the Shares, Investor Warrants, Placement Agent Warrants and the shares issuable upon exercise of the Investor Warrants and Placement Agent Warrants in the Registered Direct Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.
The description of terms and conditions of the Engagement Letter, the form of Purchase Agreement, the form of Investor Warrant and the form of Placement Agent Warrant set forth herein do not purport to be complete and are qualified in their entirety by the full text of the Engagement Letter, the form of Purchase Agreement and the form of Placement Agent Warrant, which are attached hereto as Exhibits 99.1, 10.1, 4.1 and 4.2, respectively."
The deal is at almost $10 per share. The warrants are the same price and exercisable immediately. This agreement could raise roughly $12 million for the company. A good decision by PN. He now has locked up funding for 3 years. This is plenty of time to prove at least one drug works and find a partner.
BPTH is not yet a buy for me but certainly a hold.
* * $BPTH Video Chart 11-21-2019 * *
Link to Video - click here to watch the technical chart video
You may question the timing but the raising the cash NOW is good idea. The problem is they waited too long so more dilution occurred.
QUOTES AS OF 01:32:33 PM ET 11/21/2019
Shares of Bio-Path Holdings Inc.(BPTH) are trading lower Thursday afternoon after the company announced a registered direct offering of 808,080 common shares and warrants to purchase another 606,060 common shares.
The company said "several health care-focused institutional investors" were taking part in the offering, which is expected to raise about $8 million.
At 12:53 p.m. EST, Bio-Path(BPTH) shares traded 17.04% lower at $8.12 per share. Volume topped 1.3 million shares, above the 65-day average volume of 59,583. Bio-Path(BPTH) has a market cap of $28.26 million, 2.83 million shares outstanding and a public float of 2.85 million.
Earlier in the session, shares touched as high as $11.78 after the company reported the Food and Drug Administration cleared its Investigational New Drug application for BP1002, intended for the treatment of lymphoma.
SJ was right. He usually is unfortunately. How disappointing-my take is nothing big coming anytime soon or why do this at this price:(
I just got some high 11's on pullback from 15's
BPTH
BPTH $13.00
from 15.74
Here is the earnings call transcript.
https://seekingalpha.com/article/4307110-bio-path-holdings-inc-bpth-ceo-peter-nielsen-q3-2019-results-earnings-call-transcript?page=5
There is an error in the transcript on page 5.
"And of course we have a systemic treatment that has shown the ability to penetrate the trauma in the pancreatic tumor and we are told by the investigators that this is the only thing they have seen that can do that. So we are really excited about that."
It should read "penetrate the stroma in the pancreatic tumor and we are told by the investigators that this is the only thing they have seen that can do that. So we are really excited about that."
A big deal IMO and perhaps a GAME CHANGER for BPTH.
Regarding PN's earnings call the information he now provides is excellent. I am excited about BP1003's status as the only drug with the ability to penetrate the stroma of a pancreatic cancer tumor. If this result holds up patient trials I see BP1003 as a game changer drug for this company.
I wish he would provide us with more information on this subject.
PN says cash will be needed at some time in the future via partnerships. $10 to $15 million should cover expenses until then.
There is no drug in a position for a partnership at this time. I do not believe we will have completed even a 19 patient cohort in any drug by the end of 2020. We need cash now as the burn rate is $2.2 million per quarter before ramping up additional drug trials. By then we will have $5 to $6 million in cash at best.
IMO the market decline of 10% today reflects disappointment at the lack of progress. This company's has many times in the past failed to meet timelines. I wait for that history to change. I would be ecstatic if they accelerated the efforts in all 3 drugs. Raising more cash would give the company financial security to proceed as they pleased. At 9 bucks a share the sale of 1 million shares nets 9 million in cash buying us an extra year to have drug trials in all 3 drugs well under way.
Let us hope are not raising money again at a buck a share. Why as a CEO would you take that risk?
Hard to tell if PN is excited because he is relatively monotone, but I have been listening to CCs for years and I have never heard him go on and on like this. Maybe a lot really is happening with this stock finally. He stated that the company is very well capitalized to do what it needs to do going forward. That I hope means we will not raise money anytime soon and especially at this level. Finally BPTH’s drug is the only thing that will penetrate pancreatic cancer. Most pancreatic cancer is a death sentence-anything that would help treat this would be huge! Could file IND in solid tumors next month.
Thanks for the sharing. I was very interesting to the BPTH, but the managements of the company seems too fool to make the products to the market
no posts for several weeks now.Has everyone finally woken up and running for the hills. it's nothing more than his private piggy bank
This one should slowly go up before the data is released in December.
Sure hope you are correct !
Something unlike recent run ups is in the works. This new board member will result in partnerships by year end. And PN is looking for an exit strategy that will not result in him working as the head of BPTH for the foreseeable future IMHO
That’s quite a few that have just Walked Off over the last 5 years! Hmmm......
Houston-based Bio-Path Holdings Inc. (Nasdaq: BPTH) has avoided being delisted from the Nasdaq Stock Market during a change on its board of directors.
Bio-Path, an oncology-focused biotech firm developing DNA therapeutics for cancer cells, announced that Mark Colonnese resigned as a member of the board of directors and all company committees on Oct. 10, according to an Oct. 15 filing with the U.S. Securities and Exchange Commission. Colonnese's resignation was not due to disagreement with the company on matters relating to Bio-Path's operations, policies or practices, per the filing.
However, Colonnese's resignation meant that Bio-Path was not in compliance with the Nasdaq stock exchange's continued listing requirements because the number of independent directors on the biotech firm's board, audit committee and compensation committee fell below the majority threshold.
To remedy that, Bio-Path appointed Martina Molsbergen, CEO of Malvern, Pennsylvania-based life sciences consultancy C14 Consulting, to its board as an independent director effective Oct. 11, per the filing.
“We are delighted to welcome Martina to our board of directors. Her considerable experience in business development will be invaluable as we seek a variety of partnerships and collaborations in order to advance our DNAbilize platform technology,” Peter Nielsen, president and CEO of Bio-Path Holdings, said in an Oct. 15 press release. “We thank Mark Colonnese for his considerable contributions to the board over the last two years and wish him continued success in his endeavors.”
After closing at $11.15 a share Oct. 15, Bio-Path Holdings' stock was trading down 1.43 percent to around $11 a share around midday Oct. 16, according to Yahoo Finance.
Bio-Path is a clinical- and preclinical-stage oncology company. The company's therapeutics drug candidates are in various stages of the development pipeline — from preclinical development up to Phase 2 clinical trials, according to the company's latest annual report. Products using Bio-Path's drug delivery and antisense technology, DNAbilize, are available for out-licensing or partnering.
In 2016, Bio-Path collaborated with Thomas Jefferson University in Philadelphia to target brain cancer with its DNAbilize technology.
Bio-Path was established in 2007. The company licensed technology and targets from the University of Texas M.D. Anderson Cancer Center, per the annual report. Bio-Path Holdings is headquartered at 4710 Bellaire Blvd.
Just bought some 11‘s
Followers
|
100
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6378
|
Created
|
03/26/13
|
Type
|
Free
|
Moderators |
The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.
Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.
A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.
Patent protection for manufacturing their neutral lipid delivery system has been granted.
http://www.biopathholdings.com
This link to the company website describes their delivery technology:
http://biopathholdings.com/technology/
The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |